GV has returned for a $95.4m series C round that also included Eli Lilly through the conversion of a $10m note secured as part of a collaboration agreement last year.

UK-based exosome drug developer Evox Therapeutics raised £69.2m ($95.4m) in a series C round yesterday featuring GV, a corporate venturing arm of internet technology group Alphabet, and pharmaceutical firm Eli Lilly. Redmile Group led the round and was joined by OrbiMed, Invus, University of Oxford and its patient capital fund Oxford Sciences Innovation (OSI), Panacea…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.